These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 33859363)

  • 1. Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006-2020.
    Lythgoe MP; Krell J; Savage P; Prasad V
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1208-1211. PubMed ID: 33859363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial and Ethnic Disparities in Primary Open-Angle Glaucoma Clinical Trials: A Systematic Review and Meta-analysis.
    Allison K; Patel DG; Greene L
    JAMA Netw Open; 2021 May; 4(5):e218348. PubMed ID: 34003274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
    Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
    Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research drug trials snapshot.
    Matthew-Onabanjo AN; Nortey G; Matulewicz RS; Basak R; Culton DA; Weaver KN; Gallagher KK; Tan HJ; Rose TL; Milowsky M; Bjurlin MA
    Curr Probl Cancer; 2023 Jun; 47(3):100958. PubMed ID: 37084464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial Diversity and Reporting in United States Food and Drug Administration Registration Trials for Thoracic Malignancies from 2006 to 2020.
    Chiang RS; Desai A; Glover MJ; Hui G; Ramchandran KJ; Wakelee H; Lythgoe MP; Khaki AR
    Cancer Invest; 2023 Jan; 41(1):43-47. PubMed ID: 36197034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018.
    Loree JM; Anand S; Dasari A; Unger JM; Gothwal A; Ellis LM; Varadhachary G; Kopetz S; Overman MJ; Raghav K
    JAMA Oncol; 2019 Oct; 5(10):e191870. PubMed ID: 31415071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial/Ethnic composition of study participants in FDA-approved oncology new molecular entities, 2006-2008.
    Merenda C
    J Natl Med Assoc; 2012; 104(9-10):430-5. PubMed ID: 23342816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of sex and racial subgroup participation rates and differential treatment effects for trials in solid tumor malignancies leading to US Food and Drug Administration registration between 2010 and 2021.
    Wilson BE; Nadler MB; Desnoyers A; Booth CM; Amir E
    Cancer; 2024 Jan; 130(2):276-286. PubMed ID: 37751315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inadequacy and underreporting of study subjects' race and ethnicity in federally funded pelvic floor research.
    Grimes CL; Clare CA; Meriwether KV; Husk K; Rogers RG
    Am J Obstet Gynecol; 2021 Nov; 225(5):562.e1-562.e6. PubMed ID: 34464584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diversity and transparency in gynecologic oncology clinical trials.
    Montes de Oca MK; Howell EP; Spinosa D; Knochenhauer H; Peipert BJ; Severson E; Ramkissoon S; Akinyemiju TF; Previs RA
    Cancer Causes Control; 2023 Feb; 34(2):133-140. PubMed ID: 36284031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of the globalization of cancer clinical trials on the enrollment of Black patients.
    Tharakan S; Zhong X; Galsky MD
    Cancer; 2021 Jul; 127(13):2294-2301. PubMed ID: 33682111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Race and Ethnicity Reporting and Enrollment Disparities in Clinical Trials Leading to FDA Approvals for Breast Cancer Between 2010 and 2020.
    Nguyen RH; Silva Y; Lu J; Chen Z; Gadi V
    Clin Breast Cancer; 2023 Aug; 23(6):591-597. PubMed ID: 37296063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.
    Zou CX; Becker JE; Phillips AT; Garritano JM; Krumholz HM; Miller JE; Ross JS
    Trials; 2018 Oct; 19(1):581. PubMed ID: 30352601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Disparities and Black American Representation in Clinical Trials Leading to the Approval of Oral Chemotherapy Drugs in the United States Between 2009 and 2019.
    Ajewole VB; Akindele O; Abajue U; Ndulue O; Marshall JJ; Mossi YT
    JCO Oncol Pract; 2021 May; 17(5):e623-e628. PubMed ID: 33974825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diversity in Orthopaedic Surgery Medical Device Clinical Trials: An Analysis of the Food and Drug Administration Safety and Innovation Act.
    Issa TZ; Lambrechts MJ; Lin JS; Brush PL; Canseco JA; Hilibrand AS; Kepler CK; Schroeder GD; Vaccaro AR
    J Am Acad Orthop Surg; 2023 Feb; 31(3):155-165. PubMed ID: 36525566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel.
    Mahal BA; Gerke T; Awasthi S; Soule HR; Simons JW; Miyahira A; Halabi S; George D; Platz EA; Mucci L; Yamoah K
    Eur Urol Oncol; 2022 Feb; 5(1):18-29. PubMed ID: 34446369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions.
    Rencsok EM; Bazzi LA; McKay RR; Huang FW; Friedant A; Vinson J; Peisch S; Zarif JC; Simmons S; Hawthorne K; Villanti P; Kantoff PW; Heath E; George DJ; Mucci LA
    Cancer Epidemiol Biomarkers Prev; 2020 Jul; 29(7):1374-1380. PubMed ID: 32503813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
    Miller JE; Korn D; Ross JS
    BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
    Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
    JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the FDA Safety and Innovation Act on racial and gender diversity in neurosurgical device trials.
    Siddiqui N; Chiu RG; Nunna RS; Glastris G; Mehta AI
    J Neurosurg; 2022 Jan; 136(1):274-281. PubMed ID: 34171831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.